多发性硬化症药物或添新成员:FDA批准ANK-700治疗多发性硬化症的IND

2020-09-28 Allan MedSci原创

瑞士生物技术公司Anokion SA近日宣布,美国食品药品监督管理局(FDA)已批准抗原特异性药物ANK-700治疗多发性硬化症(MS)的IND申请。

瑞士生物技术公司Anokion SA近日宣布,美国食品药品监督管理局(FDA)已批准抗原特异性药物ANK-700治疗多发性硬化症(MS)的IND申请。Anokion计划在今年年底之前启动针对MS患者的多中心I期临床试验。

Anokion首席医学官Simon Cooper表示:“多发性硬化症仍然是一种毁灭性疾病。不幸的是,可用的干预措施的获益十分有限,而且往往无法解决导致疾病恶化的潜在机制。通过利用肝脏中的天然免疫耐受途径,ANK-700旨在通过一种潜在的转化方法对免疫系统进行重新整合”。

在临床前模型中,Anokion已证明其有效的肝靶向技术诱导的耐受性T细胞机制可有效预防或减少MS的病理反应。在MS的小鼠模型中,靶向肝脏的髓磷脂少突胶质细胞糖蛋白(MOG)抗原诱导致病性T细胞无反应和缺失,从而在活动性疾病中被耐受时,可以保护免受疾病发作的影响。

 

原始出处:

https://www.firstwordpharma.com/node/1760213?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1839874, encodeId=bd8918398e470, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Oct 11 05:49:17 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890163, encodeId=ed4a1890163d4, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Aug 06 05:49:17 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983138, encodeId=ebc619831388e, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jun 11 14:49:17 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914821, encodeId=6a1d9148213b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=632f5421565, createdName=ms3000000866811638, createdTime=Sat Jan 09 10:11:32 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469173, encodeId=3ecd14691e3ae, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Wed Sep 30 00:49:17 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888879, encodeId=8a818888e976, content= 👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=632f5421565, createdName=ms3000000866811638, createdTime=Mon Sep 28 11:53:39 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888870, encodeId=16868888e087, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1995401099, createdName=ms4000001617780766, createdTime=Mon Sep 28 10:59:58 CST 2020, time=2020-09-28, status=1, ipAttribution=)]
    2020-10-11 bugit
  2. [GetPortalCommentsPageByObjectIdResponse(id=1839874, encodeId=bd8918398e470, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Oct 11 05:49:17 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890163, encodeId=ed4a1890163d4, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Aug 06 05:49:17 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983138, encodeId=ebc619831388e, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jun 11 14:49:17 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914821, encodeId=6a1d9148213b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=632f5421565, createdName=ms3000000866811638, createdTime=Sat Jan 09 10:11:32 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469173, encodeId=3ecd14691e3ae, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Wed Sep 30 00:49:17 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888879, encodeId=8a818888e976, content= 👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=632f5421565, createdName=ms3000000866811638, createdTime=Mon Sep 28 11:53:39 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888870, encodeId=16868888e087, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1995401099, createdName=ms4000001617780766, createdTime=Mon Sep 28 10:59:58 CST 2020, time=2020-09-28, status=1, ipAttribution=)]
    2021-08-06 jml2009
  3. [GetPortalCommentsPageByObjectIdResponse(id=1839874, encodeId=bd8918398e470, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Oct 11 05:49:17 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890163, encodeId=ed4a1890163d4, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Aug 06 05:49:17 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983138, encodeId=ebc619831388e, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jun 11 14:49:17 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914821, encodeId=6a1d9148213b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=632f5421565, createdName=ms3000000866811638, createdTime=Sat Jan 09 10:11:32 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469173, encodeId=3ecd14691e3ae, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Wed Sep 30 00:49:17 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888879, encodeId=8a818888e976, content= 👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=632f5421565, createdName=ms3000000866811638, createdTime=Mon Sep 28 11:53:39 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888870, encodeId=16868888e087, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1995401099, createdName=ms4000001617780766, createdTime=Mon Sep 28 10:59:58 CST 2020, time=2020-09-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1839874, encodeId=bd8918398e470, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Oct 11 05:49:17 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890163, encodeId=ed4a1890163d4, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Aug 06 05:49:17 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983138, encodeId=ebc619831388e, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jun 11 14:49:17 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914821, encodeId=6a1d9148213b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=632f5421565, createdName=ms3000000866811638, createdTime=Sat Jan 09 10:11:32 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469173, encodeId=3ecd14691e3ae, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Wed Sep 30 00:49:17 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888879, encodeId=8a818888e976, content= 👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=632f5421565, createdName=ms3000000866811638, createdTime=Mon Sep 28 11:53:39 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888870, encodeId=16868888e087, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1995401099, createdName=ms4000001617780766, createdTime=Mon Sep 28 10:59:58 CST 2020, time=2020-09-28, status=1, ipAttribution=)]
    2021-01-09 ms3000000866811638

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1839874, encodeId=bd8918398e470, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Oct 11 05:49:17 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890163, encodeId=ed4a1890163d4, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Aug 06 05:49:17 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983138, encodeId=ebc619831388e, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jun 11 14:49:17 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914821, encodeId=6a1d9148213b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=632f5421565, createdName=ms3000000866811638, createdTime=Sat Jan 09 10:11:32 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469173, encodeId=3ecd14691e3ae, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Wed Sep 30 00:49:17 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888879, encodeId=8a818888e976, content= 👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=632f5421565, createdName=ms3000000866811638, createdTime=Mon Sep 28 11:53:39 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888870, encodeId=16868888e087, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1995401099, createdName=ms4000001617780766, createdTime=Mon Sep 28 10:59:58 CST 2020, time=2020-09-28, status=1, ipAttribution=)]
    2020-09-30 xiaogang319
  6. [GetPortalCommentsPageByObjectIdResponse(id=1839874, encodeId=bd8918398e470, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Oct 11 05:49:17 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890163, encodeId=ed4a1890163d4, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Aug 06 05:49:17 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983138, encodeId=ebc619831388e, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jun 11 14:49:17 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914821, encodeId=6a1d9148213b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=632f5421565, createdName=ms3000000866811638, createdTime=Sat Jan 09 10:11:32 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469173, encodeId=3ecd14691e3ae, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Wed Sep 30 00:49:17 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888879, encodeId=8a818888e976, content= 👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=632f5421565, createdName=ms3000000866811638, createdTime=Mon Sep 28 11:53:39 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888870, encodeId=16868888e087, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1995401099, createdName=ms4000001617780766, createdTime=Mon Sep 28 10:59:58 CST 2020, time=2020-09-28, status=1, ipAttribution=)]
    2020-09-28 ms3000000866811638

    👌

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1839874, encodeId=bd8918398e470, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Oct 11 05:49:17 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890163, encodeId=ed4a1890163d4, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Aug 06 05:49:17 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983138, encodeId=ebc619831388e, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jun 11 14:49:17 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914821, encodeId=6a1d9148213b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=632f5421565, createdName=ms3000000866811638, createdTime=Sat Jan 09 10:11:32 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469173, encodeId=3ecd14691e3ae, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Wed Sep 30 00:49:17 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888879, encodeId=8a818888e976, content= 👌, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=632f5421565, createdName=ms3000000866811638, createdTime=Mon Sep 28 11:53:39 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888870, encodeId=16868888e087, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1995401099, createdName=ms4000001617780766, createdTime=Mon Sep 28 10:59:58 CST 2020, time=2020-09-28, status=1, ipAttribution=)]
    2020-09-28 ms4000001617780766

    0

相关资讯

FDA批准也是**一个多发性硬化症患者自行注射的B细胞疗法Kesimpta(ofatumumab),只需每月注射一次

Kesimpta是全人源抗CD20单抗,与特立氟胺相比,显示出优异的疗效和相似的安全性。

Acta Neurol Scand:多发性硬化症患者补充维生素D3是否会增加其疾病的复发风险?

多个队列研究发现,低循环维生素D水平与活动性MRI病变和复发的多发性硬化症(RRMS)复发的风险增加相关。然而,随机对照的补充试验在其主要终点上是阴性的,而次要的MRI终点表明有抗炎作用。循环中神经丝

NATURE:肠道微生物可以加剧多发性硬化症

越来越多的证据表明,肠道微生物在自身免疫性疾病中具有致病作用,包括多发性硬化症。对实验性自身免疫性脑脊髓炎(多发性硬化症的动物模型)以及人类的研究,已将肠道微生物联系到多发性硬化症的发展或严重程度中。

NEJM:诺华每月注射一次的奥法木单抗ofatumumab在多发性硬化症患者中展现优越疗效

如果获批,ofatumumab将成为首个患者可以自行注射治疗的B细胞疗法,并且有可能成为复发型多发性硬化症的首选疗法。

JAMA Neurol:继发性进行性多发性硬化症患者持续接受免疫治疗可降低残疾进展风险

对于继发性进行性多发性硬化症患者积极接受疾病修饰治疗可改善残疾结局

EBV特异性T细胞免疫疗法ATA188治疗多发性硬化症:所有剂量组均取得积极结果

生物制药公司Atara的研究性药物ATA188治疗多发性硬化症(MS)取得积极进展。ATA188是一款异基因EBV特异性T细胞免疫疗法。

拓展阅读

《新英格兰杂志》:CD40L抗体Frexalimab对多发性硬化症的作用

在此项使用Frexalimab治疗MS患者第2阶段试验中,CD40L抗体在治疗第12周,更有利于减少钆增强T1加权病变的新损伤数量。

JNNP: 复发缓解型多发性硬化症的造血干细胞移植——一项观察性队列研究

使用aHSCT治疗RRMS可使大多数患者摆脱疾病活动,且不良反应可接受。

Neurology:脊髓萎缩和脑顺磁环病变与多发性硬化症患者病情进展或复发活动的相关性

PIRA 与脊髓萎缩和 PRL 负担的增加有关,这种关联在 RRMS 患者中也很明显。

JNNP:多发性硬化症患者的心肺功能和磁共振成像神经炎症测量对海马体积的影响

较好的 CRF 可对多发性硬化症患者的海马完整性起到特殊的神经保护作用,但仅限于疾病的复发缓解阶段。

Annals of neurology:高水平的血管周围炎症和活动性脱髓鞘病变与快速进展性多发性硬化症病程有关

ALs 是疾病早期阶段的一个特征,在 PVI 水平较高的MS亚组换着中持续存在直到死亡。

Annals of neurology:多发性硬化皮层缺氧的时间模式及其对神经心理学和功能残疾的意义

fdNIRS 参数具有很高的再现性和可重复性,目前的结果已经证明多发性硬化症缺氧是一种慢性疾病,至少会持续一年。